ReviewPharmaceutics2025
Biomedical Applications of Functionalized Composites Based on Metal-Organic Frameworks in Bone Diseases.
Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Liposomal multimodal theranostics for bone disorders: from rational responsive delivery and biomimetic strategies to clinical translation.Journal of nanobiotechnology · 2026Review
- Safety, In Vivo Fate, and Degradation of MOF Nanomedicines: Toward Translational Evaluation.Pharmaceutics · 2026Review
- Bibliometric and visualized analysis of metal‒organic frameworks in bone tissue engineering and bone diseases.Discover nano · 2026Review
- Regulation of bone immunity by metal ions: a review of mechanisms and application progress.Frontiers in immunology · 2026Review
- Hydroxyapatite-based bone repair biomaterials based on clinical heterogeneity: modification strategies, performance regulation, and personalized repair pathways.Frontiers in bioengineering and biotechnology · 2026Review
- Converging chemistry and clinical orthopedics in the emerging role of MOFs in advanced bone defect repair.Theranostics · 2026Review
- An Update Regarding the Use of Contemporary Dental Materials in Periodontal Regeneration.Materials (Basel, Switzerland) · 2025Review
- Emerging Role of Enzyme-Immobilized Nanocarriers in Osteoporosis: Advances and Challenges.International journal of nanomedicine · 2025Review
- Functionalized metal-organic framework and MOF-derived materials for bone regeneration applications.Frontiers in bioengineering and biotechnology · 2025Review
- Recent advances in metal-organic frameworks for therapeutic applications in periodontitis.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Every year, millions of people worldwide suffer from bone tissue damage caused by bone trauma and surgical operations, as well as diseases such as osteoporosis, osteoarthritis, osteomyelitis, and periodontitis. Bone defect repair is one of the major challenges in the field of regenerative medicine. Although bone grafts are the gold standard for treating bone defects, factors such as donor sources and immune responses limit their application. Functionalized nanomaterials have become an effective means of treating bone diseases due to their good biocompatibility and osteoinductivity, anti-inflammatory, and antibacterial properties. Metal-organic frameworks (MOFs) are porous coordination polymers composed of metal ions and organic ligands, featuring unique physical properties, including a high surface area-volume ratio and porosity. In regenerative medicine, MOFs function as the functions of drug carriers, metal ion donors, nanozymes, and photosensitizers. When combined with other functional materials, they regulate cellular reactive oxygen species, macrophage phenotypic transformation, bone resorption, osteogenesis, and mineralization, providing a new paradigm for bone tissue engineering. This study reviews the classification of functionalized MOF composites in biomedicine and the application of their synthesis techniques in bone diseases. The unique in vivo and in vitro applications of MOFs in bone diseases, including osteoarthritis, osteoporosis, bone tumors, osteomyelitis, and periodontitis, are explored. Their properties include excellent drug loading and sustained release abilities, high antibacterial activity, and bone induction abilities. This review enables readers to better understand the cutting-edge progress of MOFs in bone regeneration applications, which is crucial for the design of and functional research on MOF-related nanomaterials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.